Abstract
Background/Aims: We have found that HGF (hepatocyte growth factor) can be a therapeutic agent for liver disorders, including fulminant hepatic failure, regardless administrations of recombinant protein or the gene therapy strategy (Ref 1-3). On the other hand, heparin-binding epidermal growth factor-like growth factor (HB- EGF), a unique membrane-anchored growth factor, is more rapidly increased after liver injury than HGF, suggesting another hepatotrophic factor. However, the therapeutic potential of HB- EGF for liver disorders has not yet been studied.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
